



King's Research Portal

DOI:

[10.1038/s41590-019-0377-2](https://doi.org/10.1038/s41590-019-0377-2)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Drummond, R. A., Swamydas, M., Oikonomou, V., Zhai, B., Dambuza, I. M., C. Schaefer, B., Bohrer, A. C., D. Mayer-Barber, K., A. Lira, S., Iwakura, Y., G. Filler, S., D. Brown, G., Hube, B., Naglik, J. R., M. Hohl, T., & S. Lionakis, M. (2019). CARD9⁺ microglia promote antifungal immunity via IL-1- and CXCL1-mediated neutrophil recruitment. *Nature Immunology*, 20(5), 559-570. <https://doi.org/10.1038/s41590-019-0377-2>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

CARD9⁺ Microglia Orchestrate Antifungal Immunity via IL-1 β and CXCL1-mediated Neutrophil Recruitment

CARD9⁺ Microglia Promote Antifungal Immunity via IL-1 β and CXCL1-mediated Neutrophil Recruitment

CARD9⁺ Microglia Protect from Fungal Invasion via IL-1 β and CXCL1-mediated Neutrophil Recruitment

Rebecca A. Drummond^{1*†}, Muthulekha Swamydas^{1#}, Vasileios Oikonomou^{1#}, Bing Zhai^{2#}, Ivy M. Dambuza³, Brian C. Schaefer⁴, Andrea C. Bohrer⁵, Katrin D. Mayer-Barber⁵, Sergio A. Lira⁶, Yoichiro Iwakura⁷, Scott G. Filler⁸, Gordon D. Brown³, Bernhard Hube^{9,10}, Julian R. Naglik¹¹, Tobias M. Hohl², Michail S. Lionakis^{1*}

¹Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy & Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

²Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

³Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK

⁴Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814

⁵Inflammation and Innate Immunity Unit, LCIM, NIAID, NIH, Bethesda, MD, USA

⁶Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

⁷Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan

25 ⁸ Division of Infectious Diseases, Department of Medicine, Los Angeles Biomedical Research Institute at Harbor—
26 UCLA, Torrance, CA, 90502

27 ⁹Department of Microbial Pathogenicity Mechanisms; Leibniz Institute for Natural Product Research and Infection
28 Biology; Hans Knöll Institute Jena; Jena, Germany

29 ¹⁰Friedrich Schiller University, Jena, Germany

30 ¹¹Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College
31 London, London, United Kingdom

32

33 †Current address: Institute of Immunology & Immunotherapy, Institute of Microbiology & Infection, University of
34 Birmingham, Birmingham B15 2TT, UK

35

36 #These authors contributed equally to this work

37

38 *Correspondence: r.drummond@bham.ac.uk; lionakism@niaid.nih.gov

39 **Abstract**

40

41 The C-type lectin receptor–Syk adaptor CARD9 facilitates protective antifungal immunity within
42 the central nervous system (CNS), as human CARD9-deficiency causes fungal-specific CNS-
43 targeted infection susceptibility. CARD9 promotes neutrophil recruitment to the fungal-infected
44 CNS, which mediates fungal clearance. Here, we investigated host and pathogen factors that
45 promote protective neutrophil recruitment during *Candida albicans* CNS invasion. IL-1 β was
46 essential for CNS antifungal immunity by driving CXCL1 production, which recruited CXCR2-
47 expressing neutrophils. Neutrophil-recruiting IL-1 β and CXCL1 production was induced in
48 microglia by the fungal-secreted toxin Candidalysin, in a p38-cFos-dependent manner.
49 Importantly, microglia relied on CARD9 for production of IL-1 β , via both *Il1b* transcriptional
50 regulation and inflammasome activation, and of CXCL1 in the fungal-infected CNS. Microglia-
51 specific *Card9* deletion impaired IL-1 β and CXCL1 production and neutrophil recruitment, and
52 increased CNS fungal proliferation. Taken together, an intricate network of host-pathogen
53 interactions promotes CNS antifungal immunity, which is impaired in human CARD9-deficiency
54 leading to CNS fungal disease.

55 **Introduction**

56

57 The CNS is invaded by microorganisms during systemic infections, yet the mechanisms of
58 CNS-specific anti-microbial immunity remain poorly-understood. This is particularly true for
59 CNS fungal infections, which present unmet diagnostic and treatment challenges, leading to
60 unacceptably high mortality rates (>50%)¹. Fungal CNS invasion is enhanced by fungal-
61 specific risk factors, including HIV infection, neutropenia, corticosteroid use, and Bruton's
62 tyrosine kinase inhibition¹. However, the most striking human risk factor for selective CNS
63 fungal infection susceptibility is inherited deficiency of the C-type lectin receptor (CLR)–Syk
64 adaptor CARD9.

65

66 CARD9 relays fungal-sensing signals downstream of the CLR superfamily of pattern
67 recognition receptors, including Dectin-1, Dectin-2, Dectin-3 and Mincle. Syk kinase is
68 recruited to phosphorylated ITAM sequences of CLRs or their signaling partner FcRγ to form
69 the CARD9-BCL10-MALT1 signalosome, which activates downstream effectors including
70 NFκB, NLRP3 inflammasome and MAPK signaling².

71

72 CARD9-deficient patients manifest fungal-specific infection susceptibility, predominantly in the
73 CNS by *Candida albicans*²⁻⁴. We previously showed that CARD9-deficiency in humans and
74 mice confers a fungal- and brain-specific defect in neutrophil recruitment, which is detrimental
75 for control of CNS fungal invasion⁵. However, the CNS cellular and molecular cues that
76 promote protective neutrophil recruitment during *C. albicans* invasion and their dependence on
77 CARD9 *in vivo* remain unknown.

78

79 Herein, we systematically investigated host and pathogen factors that promote protective
80 neutrophil influx into the *C. albicans*-infected CNS to better understand the pathogenesis of
81 human CARD9-deficiency. We uncover an intricate pathway by which the *C. albicans*-secreted
82 toxin Candidalysin engages microglia to produce IL-1 β and CXCL1 for protective recruitment of
83 CXCR2-expressing neutrophils. Importantly, microglial IL-1 β and CXCL1 production depends
84 on CARD9 and specific deletion of microglial CARD9 impairs neutrophil recruitment to the *C.*
85 *albicans*-infected CNS. Collectively, our data unveil complex host-pathogen interactions that
86 recruit protective neutrophils during fungal CNS invasion and reveal the mechanism that
87 underlies CNS fungal susceptibility in CARD9-deficiency.

Results

CLR Functional Redundancy during Fungal CNS Invasion

As previously shown, CARD9 is essential for protective CNS immunity against *C. albicans*, principally through promoting early neutrophil recruitment (**Fig. 1a**). We first investigated the relative contribution of CARD9-coupled CLRs, which are expressed by brain-resident microglia (**Supplementary Fig. 1**), in mediating this protective neutrophil recruitment. We infected mice deficient in Dectin-1 (*Clec7a*^{-/-}), Dectin-2 (*Clec4e*^{-/-}), Dectin-3 (*Clec4d*^{-/-}) and Mincle (*Clec4e*^{-/-}) and measured brain neutrophil accumulation at 24 h post-infection (**Supplementary Fig. 2**). We chose this time-point since it is the peak of the neutrophil response in wild-type animals and neutrophil depletion at this time-point increases susceptibility to brain fungal invasion⁵.

Animals individually deficient in CARD9-coupled CLRs recruited neutrophils to the infected brain normally (**Fig. 1b**). Despite this, we observed increases in fungal brain burdens at 72 h post-infection in mice deficient in Dectin-1 or Dectin-2 but not Dectin-3 or Mincle (**Fig. 1c**), suggesting that Dectin-1 and Dectin-2 employ neutrophil recruitment-independent mechanisms to protect against brain fungal proliferation. Indeed, brain-infiltrating neutrophils from Dectin-1- and Dectin-2-deficient animals exhibited reduced fungal phagocytosis (**Supplementary Fig. 3**), consistent with prior findings⁶.

To activate CARD9-dependent signaling, phosphorylation occurs on the ITAM sequence within the intracellular tail of Dectin-1 or FcRγ, which Dectin-2, Dectin-3 and Mincle associate with. Therefore, we assessed whether deletion of all four CLRs affected the neutrophil response in

111 the infected brain. We used mice doubly-deficient in Dectin-1 and FcR γ (*Clec7a*^{-/-}*Fcerg1*^{-/-}) and
112 found that loss of both Dectin-1 and the FcR γ -coupled CLRs phenocopied Card9-deficiency
113 with significantly decreased neutrophil recruitment and corresponding increased brain fungal
114 burdens (**Fig. 1b,c**). Taken together, CARD9-coupled CLRs functionally compensate to
115 mediate neutrophil recruitment-dependent protection against *C. albicans* CNS invasion.

116

117 **MALT1 is Required for Defense against CNS Candidiasis**

118 The CARD9-MALT1-BCL10 signalosome is necessary for transducing fungal-sensing
119 intracellular signals. Human deficiencies of MALT1 or BCL10 cause defective innate and
120 adaptive immune responses, and many of these patients die in childhood from bacterial and
121 viral infections². Human MALT1-deficiency additionally manifests with mucosal candidiasis,
122 suggesting that antifungal immunity is impaired in these patients. However, whether MALT1-
123 deficiency also predisposes to brain-targeted candidiasis is unknown. To test this, we infected
124 Malt1-deficient mice and assessed control of CNS *C. albicans* growth. *Malt1*^{-/-} animals
125 recruited neutrophils to the brain similarly to wild-type, however these animals exhibited
126 uncontrolled brain fungal growth at 72 h post-infection (**Fig. 1d**). Therefore, MALT1 is critical
127 for protective CNS immunity against *C. albicans*; however, the MALT1-dependent protective
128 mechanisms operating in this tissue are independent of neutrophil recruitment, unlike CARD9.

129

130 **Candida Drives CNS Neutrophil Influx via IL-1 β and CXCL1**

131 To determine the local cues that recruit protective neutrophils in the infected CNS, we
132 examined key cytokine and chemokine circuits using gene-deficient mice. We first infected IL-1
133 receptor (IL-1R)-deficient mice, because production of IL-1 β by human peripheral blood

134 mononuclear cells upon fungal stimulation is CARD9-dependent^{5,7}, and because IL-1R was
135 previously shown to recruit neutrophils to fungal-infected mucosal tissues^{8,9}, and to the
136 bacterial-infected brain¹⁰. Upon *C. albicans* challenge, IL-1R-deficient mice phenocopied
137 Card9-deficient mice, with a loss of early brain neutrophil recruitment and accompanying
138 increased fungal brain burdens (**Fig. 2a,b**). Consistent with this, loss of the IL-1R signaling
139 adaptor MyD88 caused similar defects in neutrophil recruitment and control of fungal
140 proliferation in the infected brain (**Fig. 2a,b**).

141
142 We next assessed which IL-1R ligands were important for driving CNS protection by infecting
143 mice deficient in IL-1 α , IL-1 β or both. Mice lacking IL-1 α had a small reduction in neutrophil
144 numbers and a slight increase in fungal brain burden at 24 h post-infection (**Fig. 2a,b**).
145 However, the lack of IL-1 α was compensated by IL-1 β , since *Il1a*^{-/-} animals recovered and
146 controlled fungal brain infection similar to wild-type by 72 h post-infection (**Fig. 2b**). In keeping
147 with the critical contribution of IL-1 β , mice deficient in IL-1 β , or both IL-1 α -IL-1 β , exhibited
148 significantly reduced neutrophil accumulation and were highly susceptible for fungal brain
149 invasion (**Fig. 2a,b**). Therefore, IL-1 β is a critical mediator of neutrophil recruitment to promote
150 control of *C. albicans* brain infection.

151
152 Downstream of IL-1R, local chemotactic mediators recruit immune cells to infected tissues.
153 Previously, we showed that the CNS-neutropenia observed in mouse and human CARD9-
154 deficiency is not caused by neutrophil-intrinsic chemotaxis defects⁵, but by insufficient local
155 production of soluble chemotactic mediators. However, which among the several

chemoattractants and their receptors recruit(s) protective neutrophils to the *C. albicans*-infected CNS is unknown.

CARD9 was shown to drive production of the CXCR2 ligands CXCL1 and CXCL2 during inflammatory arthritis¹¹ and murine subcutaneous phaeohyphomycosis¹². During systemic *C. albicans* infection, CCR1 drives renal neutrophil accumulation and immune-related kidney destruction¹³, the leukotriene B4 (LTB₄) receptor LTB4R1 promotes detrimental pulmonary neutrophil accumulation¹⁴, and CXCR1 mediates neutrophil-dependent fungal killing in the kidney¹⁵. However, the role of these receptors in CNS anti-*Candida* immunity is unknown, while CXCR2 and the fMet-Leu-Phe (fMLP) receptor FPR1 have not been examined in anti-*Candida* defense.

To test the relative dependence on these major neutrophil-targeted chemoattractant receptors in protecting the fungal-infected brain, we infected mice deficient in CCR1, CXCR1, CXCR2, LTB4R1 or FPR1 and measured neutrophil recruitment and fungal brain burdens. We found no involvement of the CCL3–CCR1, CXCL5–CXCR1, LTB₄–LTB4R1 or fMLP–FPR1 axes in controlling fungal brain infection, in line with normal early neutrophil recruitment in infected *Ccr1*^{-/-}, *Cxcr1*^{-/-}, *Ltb4r1*^{-/-} and *Fpr1*^{-/-} animals (**Fig. 2c,d and Supplementary Fig. 4**). In contrast, CXCR2-deficient mice had significantly reduced neutrophil accumulation and corresponding significantly increased fungal brain growth (**Fig. 2c,d**). These data demonstrate the importance of the CXCR2 axis in neutrophil-mediated protection against *C. albicans* brain infection.

179 Next, we wondered which CXCR2 ligand may recruit protective neutrophils to the fungal-
180 infected brain. We infected *Cxcl1*^{-/-} mice that lack expression of the potent neutrophil
181 chemokine CXCL1. Notably, these animals had decreased neutrophil recruitment to the brain
182 post-infection and exhibited a similar CNS invasion susceptibility phenotype to *Cxcr2*^{-/-} mice
183 (**Fig. 2c,d**). Therefore, the CXCL1–CXCR2 chemokine axis is critical for protection against *C.*
184 *albicans* brain invasion by recruiting protective neutrophils. Importantly, this data indicates that
185 the reduced CXCL1 in the human CARD9-deficient *C. albicans*-infected cerebrospinal fluid is
186 biologically relevant and significant⁵.

187

188 **IL-1 β Activates CXCL1 in the Fungal-Infected Brain**

189 Since both IL-1 β and CXCL1 were required for protection, we investigated whether their
190 activation in the infected brain was simultaneous or sequential. We measured IL-1 β and
191 CXCL1 in brain homogenates at 24 h post-infection in animals lacking these inflammatory
192 mediators. We found no defect in IL-1 β levels in CXCL1-deficient infected brains; however, we
193 discovered a significant defect in CXCL1 production in the absence of IL-1 β (**Fig. 3a**). To
194 define the IL-1 β –dependent brain cellular sources of CXCL1, we infected wild-type and IL-1 β –
195 deficient mice and used intracellular flow cytometry. CXCL1 and pro-IL-1 β were produced by
196 multiple myeloid phagocytes in the fungal-infected brain, including resident microglia, the most
197 numerous immune cells in the brain, recruited Ly6C^{hi} monocytes which have been implicated
198 in controlling *C. albicans* CNS invasion¹⁶, and neutrophils themselves (**Fig. 3b**). Interestingly,
199 *Il1b*^{-/-} microglia recovered from *C. albicans*-infected brains had a profound defect in CXCL1
200 production, exhibiting significant reductions under every *ex vivo* restimulation condition tested
201 (**Fig. 3c**). Ly6C^{hi} monocytes isolated from *Il1b*^{-/-} *C. albicans*-infected brains produced less

202 CXCL1 when restimulated *ex vivo* with LPS, with no differences detected under non-stimulated
203 or zymosan-stimulated conditions. Neutrophil production of CXCL1 did not differ between the
204 two mouse groups (**Fig. 3c**). Therefore, IL-1 β is required for subsequent CXCL1 production
205 from resident microglia and recruited monocytes, which in turn recruits CXCR2-expressing
206 neutrophils to the fungal-infected brain.

207 208 **Candidalysin is a Fungal Avirulence Factor in the Brain**

209 Use of genetically-deficient mice allowed us to map the host pathway promoting protection
210 against *C. albicans* brain infection, in which IL-1 β –IL-1R–MyD88 signaling activates CXCL1
211 production by resident microglia and recruited monocytes to mobilize neutrophils into the CNS.
212 To identify the pathogen-associated factors that induce this protective host pathway, we
213 infected animals with *C. albicans* strains lacking known virulence factors and assessed
214 neutrophil recruitment and IL-1 β and CXCL1 production in the infected brain.

215
216 *C. albicans* hyphae are the predominant CNS-invasive morphological forms of *C. albicans*⁵
217 and hyphal formation is associated with important virulence traits such as toxin and protease
218 production, adhesion, invasion, and immune system activation¹⁷. Thus, we first asked whether
219 neutrophil recruitment was impaired during infection with the *hgc1* Δ/Δ *C. albicans* strain which
220 cannot filament *in vivo*¹⁸. Indeed, infection with hypha-deficient *hgc1* Δ/Δ *C. albicans*
221 significantly impaired neutrophil recruitment and enhanced fungal CNS tissue invasion relative
222 to the isogenic wild-type *C. albicans* strain (**Fig. 4a**). Thus, strikingly, filamentation is not
223 required for *C. albicans* invasion of brain tissue, in contrast to other organs such as the
224 kidney¹⁸.

225

226 Candidalysin is a recently-described peptide toxin encoded by *ECE1* and expressed
227 exclusively by *C. albicans* hyphae¹⁹. Candidalysin was shown to mediate epithelial cell
228 damage via pore formation in the plasma cell membrane resulting in IL-1 α release and pro-
229 inflammatory cytokine production. Hence, Candidalysin-null mutants were highly attenuated in
230 murine oropharyngeal and vulvovaginal candidiasis models¹⁹⁻²¹. Instead, we found that lack of
231 Candidalysin promoted brain infection, and that this phenotype was specific to the
232 Candidalysin peptide since mutant strains deficient in the entire gene (*ece1* Δ/Δ) or specifically
233 in the Candidalysin-encoding portion of the gene (*ece1* Δ/Δ + *ECE1* $\Delta_{184-279}$) were both hyper-
234 virulent for *C. albicans* brain invasion (**Fig. 4b**).

235

236 The increased ability of the Candidalysin-null mutants to proliferate within the brain directly
237 correlated with the degree of neutrophil recruitment. We found a near absence of neutrophils in
238 the brains of wild-type animals infected with Candidalysin-null strains and observed hyphal
239 forms growing in the brain parenchyma without neutrophilic reaction (**Fig. 4c**). In contrast, the
240 Candidalysin-producing parental strain and the re-integrant control strain promoted neutrophil
241 recruitment at 24 h post-infection, and these neutrophils clustered around invading hyphae
242 (**Fig. 4c**). In line with the absence of neutrophils in the brains of mice infected with
243 Candidalysin-null strains, IL-1 β and CXCL1 were significantly reduced in brain homogenates
244 from animals infected with these strains (**Fig. 4d**). Therefore, Candidalysin is a key fungal
245 factor that activates the IL-1 β –CXCL1 protective pathway *in vivo*. Notably, in contrast to its role
246 in the mucosa, Candidalysin acts as an avirulence factor in the brain by instigating protective

247 host CNS immunity, underscoring the tissue-specific opposing roles that a microbial factor may
248 play during infection with the same pathogen¹⁷.

249

250 We next wondered whether other *C. albicans* hyphae-associated secreted proteins also
251 activate protective neutrophil responses in the brain. Secreted aspartyl proteases (Saps) are
252 enzymes with extracellular proteolytic activity and are linked to virulence²². *C. albicans* Saps
253 promote neutrophil recruitment during vulvovaginal candidiasis in mice^{23,24}. Expression of the
254 *SAP4-6* subfamily is coordinately regulated with hyphal formation²², therefore we tested
255 whether these hyphal-associated Saps contributed towards virulence during brain invasion.
256 Wild-type animals infected with the triple-deficient strain *sap4/5/6Δ/Δ* had comparable brain
257 fungal burdens to animals infected with the complemented control strain (**Fig. 4e**). In line with
258 this, we saw no difference in CNS neutrophil recruitment in these animals, indicating that *C.*
259 *albicans* Saps exhibit tissue-specific roles in promoting neutrophil recruitment during
260 infection^{23,24} (**Fig. 4e**). Therefore, protective CNS neutrophil recruitment is activated by
261 Candidalysin, and not by other *C. albicans* hyphae-secreted enzymes.

262

263 **Candidalysin Drives Microglial IL-1 β and CXCL1 *in vivo***

264 We next sought to define the Candidalysin-responsive CNS immune cells post-infection. We
265 infected wild-type mice with the parental strain of *C. albicans* (BWP17) or the Candidalysin-null
266 strain (*ece1Δ/Δ*), and analyzed IL-1 β and CXCL1 production at 24 h post-infection. Although all
267 brain phagocytes produced both IL-1 β and CXCL1, microglia were the only population to
268 exhibit dependence on Candidalysin, since microglia isolated from *ece1Δ/Δ*-infected brains
269 produced significantly less IL-1 β and CXCL1 *ex vivo* (**Fig. 5a,b**). Instead, Ly6C^{hi} monocytes

270 and neutrophils did not depend on Candidalysin for IL-1 β and CXCL1 production, suggesting
271 that other as-yet unidentified fungal factors activate this pathway in these phagocytes.
272 Together, our data show that Candidalysin acts on microglia to stimulate IL-1 β release, which
273 then drives CXCL1 production that is required for protective neutrophil CNS recruitment.

274

275 **Candidalysin Drives Differing Glial IL-1 β –CXCL1 *ex vivo***

276 To gain mechanistic insights into how microglia respond to Candidalysin, we cultured the
277 microglia cell line BV-2²⁵ in the presence of synthetic Candidalysin and measured IL-1 β and
278 CXCL1 in the supernatants. In line with our *in vivo* work, we found time- and dose-dependent
279 IL-1 β production by BV-2 cells in response to Candidalysin (**Fig. 6a**). However, we did not
280 detect CXCL1 from BV-2 cells stimulated under these conditions. We first considered that this
281 could be due to Candidalysin-induced damage that may prevent BV-2 cells from producing
282 CXCL1 after IL-1 β secretion. Indeed, as shown for epithelial cells¹⁹, Candidalysin mediated
283 dose-dependent cell damage to BV-2 microglia (**Fig. 6b**). Alternatively, additional signals
284 beyond IL-1 β , derived from non-microglial CNS cells, might be required for microglial CXCL1
285 induction, acting *in trans*. To test this hypothesis, we co-cultured BV-2 cells with immortalized
286 C8-D1A astrocytes in the presence of Candidalysin and measured IL-1 β and CXCL1 in the
287 supernatants. We chose astrocytes since they are known to respond to IL-1 β to produce
288 inflammatory mediators, including CXCL1, in other models of CNS inflammation²⁶⁻²⁸. We found
289 that astrocytes responded to Candidalysin to produce CXCL1 (**Fig. 6c**), but not IL-1 β (data not
290 shown), and that CXCL1 production significantly increased when astrocytes and microglia
291 were co-cultured (**Fig. 6c**). To confirm that microglia are a relevant cellular source of CXCL1
292 detected during microglia-astrocyte co-culture, we performed intracellular staining for CXCL1

293 and found that BV-2 microglia are significant producers of CXCL1 in response to Candidalysin,
294 but only when astrocytes were present (**Fig. 6d**). Therefore, astrocytes provide additional
295 signals to microglia that are needed for CXCL1 production in response to Candidalysin.

296

297 We next investigated the pathway activated by Candidalysin in BV-2 microglia to produce IL-
298 1 β . Candidalysin was previously shown in epithelial cells to activate c-Fos, in a p38-dependent
299 manner, and the phosphatase MKP-1²⁰. We thus asked whether the same pathways are
300 activated by Candidalysin in BV-2 microglia. We found that Candidalysin sequentially and
301 dose-dependently activated MKP-1 and c-Fos (**Fig. 6e**), and chemical inhibition of p38 or c-
302 Fos significantly reduced IL-1 β release by Candidalysin-stimulated BV-2 cells (**Fig. 6f**).

303 Therefore, microglia produce IL-1 β in response to Candidalysin via activation of p38 and c-
304 Fos.

305

306 **The Microglial IL-1 β –CXCL1 Response Requires CARD9**

307 CARD9-deficiency is the only known risk factor that uniquely predisposes to CNS candidiasis
308 in the absence of iatrogenic intervention^{2,5}. We first examined whether CARD9-deficiency
309 causes developmental defects in resident microglia, but found no defects in abundance or
310 activation markers at steady state in *Card9*^{-/-} microglia, which accumulated in similar numbers
311 as wild-type microglia after fungal infection (**Supplementary Fig. 5**). Since *C. albicans*
312 activates the microglial IL-1 β –CXCL1 axis to regulate protective neutrophil CNS recruitment,
313 we next analyzed the dependence on CARD9 for induction of this pathway in microglia post-
314 infection *in vivo*. We hypothesized that CARD9 is required for these functions, as microglia
315 highly-express CARD9 and we previously found reduced transcription of CXC chemokines by

316 *Card9*^{-/-} microglia harvested from the *C. albicans*-infected brain⁵. We infected *Card9*^{+/+} and
317 *Card9*^{-/-} animals with wild-type Candidalysin-expressing *C. albicans*, isolated phagocytes from
318 the brain and measured pro-IL-1 β and CXCL1 production following *ex vivo* restimulation. We
319 found significantly decreased frequencies of CXCL1⁺ and pro-IL-1 β ⁺ cells in the fungal-infected
320 *Card9*^{-/-} brain, and these decreases mapped to microglia (**Fig. 7a,b**).

321
322 Since production and secretion of mature IL-1 β depends on pro-IL-1 β expression and
323 consecutive inflammasome-dependent processing, we asked whether microglia depend on
324 CARD9 for pro-IL-1 β transcription and/or inflammasome activation. We FACS-sorted microglia
325 from wild-type and *Card9*^{-/-} infected brains, and examined *Il1b* transcription by qRT-PCR, and
326 levels of pro-IL-1 β and cleaved and pro-caspase-1 by immunoblot. We found significantly
327 decreased *Il1b* transcription in *Card9*^{-/-} microglia, which we confirmed at the protein level (**Fig.**
328 **7c,d**). These data are in line with the reported CARD9-dependent pro-IL-1 β transcription in
329 bone marrow-derived dendritic cells post-viral infection²⁹. We also found significantly reduced
330 cleaved caspase-1 in *Card9*^{-/-} microglia (**Fig. 7d**), indicating that Card9 also operates at the
331 level of inflammasome activation for IL-1 β production. Given that c-Fos mediated
332 Candidalysin-induced IL-1 β production by BV-2 cells, we measured c-Fos expression in WT
333 and *Card9*^{-/-} microglia by immunoblot and found significantly decreased c-Fos expression in
334 *Card9*^{-/-} microglia (**Fig. 7d**).

335
336 We next examined the NLRP3 inflammasome in FACS-sorted WT and *Card9*^{-/-} microglia. We
337 focused on NLRP3 because CARD9 was reported to negatively regulate NLRP3 activation
338 during macrophage *Salmonella* infection³⁰, and we recently showed that Candidalysin

339 activates NLRP3 in bone marrow-derived macrophages³¹. We found significantly decreased
340 NLRP3 protein expression in *Card9*^{-/-} microglia (**Fig. 7e**). Of interest, *Nlrp3*^{-/-} animals had
341 significantly decreased neutrophil accumulation to the *C. albicans*-infected brain and increased
342 fungal load post-infection, consistent with a potential role of Card9-dependent NLRP3-
343 inflammasome activation for protective neutrophil influx in the fungal-infected CNS (**Fig. 7f**).
344 Together, microglia require CARD9 for c-Fos activation and for production of mature IL-1 β via
345 *Il1b* transcriptional regulation and inflammasome activation, to activate the IL-1 β –CXCL1 axis
346 in response to fungal invasion.

347 348 **Microglial CARD9 Deletion Causes CNS Fungal Invasion**

349 We next directly examined the impact of genetic *Card9* deletion specifically within microglia by
350 utilizing mice expressing tamoxifen-inducible Cre recombinase under the *Cx3cr1* promoter
351 (*Cx3cr1*^{CreER})³². These mice has been used to genetically manipulate long-lived CX3CR1⁺
352 microglia while leaving short-lived CX3CR1⁺ monocytes and monocyte-derived macrophages
353 unaffected. We bred *Cx3cr1*^{CreER} animals to *Card9*-floxed mice¹¹, tamoxifen-pulsed the
354 progeny to activate Cre expression and waited 4-6 weeks to allow replenishment of short-lived
355 non-microglia CX3CR1⁺ cells from the bone marrow, while long-lived microglia remained
356 *Card9*-deficient (**Supplementary Fig. S6**). *C. albicans* infection of *Card9*^{fl/fl}*Cx3cr1*^{CreER+/-}
357 animals revealed a significant dependence on *Card9* expression by the long-lived CX3CR1⁺
358 cellular compartment for control of fungal brain growth (**Fig. 8a**), while renal fungal control was
359 unaffected in microglia-specific conditional *Card9*^{-/-} mice (**Fig. 8a**).

360

361 To analyze whether the susceptibility to brain infection in *Card9^{fl/fl}Cx3cr1^{CreER+/-}* mice was
362 related to a neutrophil recruitment defect, we quantified neutrophils within the infected brains of
363 *Card9^{fl/fl}Cx3cr1^{CreER+/-}* mice and their Cre-negative littermates. We found that microglial
364 deletion of *Card9* significantly reduced the protective early influx of neutrophils into the fungal-
365 infected brain (**Fig. 8b**), which correlated with significantly decreased expression of microglial
366 pro-IL1 β and CXCL1 in the conditional *Card9^{-/-}* mice (**Fig. 8c**). Together, our data shows that
367 CARD9-expressing microglia orchestrate control of fungal brain invasion by responding to
368 fungus-secreted Candidalysin to produce IL-1 β –induced CXCL1, which recruits CXCR2-
369 expressing neutrophils that mediate CNS fungal clearance (**Supplementary Fig. S7**).

Discussion

Herein, we demonstrate the critical contribution of CARD9-mediated IL-1 β and CXCL1 in recruiting protective neutrophils to the fungal-infected CNS. We identify microglia as major producers of CARD9-dependent IL-1 β and CXCL1 during *C. albicans* CNS invasion and the fungal-secreted toxin Candidalysin as a critical pathogen-derived factor activating this pathway. Our study offers novel insights into the network of host and fungal factors that protect against CNS fungal invasion and unveil the mechanism of CNS fungal susceptibility in inherited CARD9-deficiency.

Systemic candidiasis is a leading cause of nosocomial bloodstream infection with mortality >50% despite therapy³³. Neutropenia is the major predisposing factor for systemic candidiasis and *Candida* CNS invasion in particular^{1,34}. Moreover, CNS invasion is prevalent during systemic candidiasis in low-birth weight neonates and also occurs as an iatrogenic complication post-neurosurgical procedures^{35,36}. Strikingly, CARD9-deficiency is a primary immunodeficiency disorder (PID) characterized by heightened susceptibility to fungal infections of which CNS candidiasis is a hallmark^{2,34}. CARD9-deficiency is the only known PID that causes fungal-specific infection susceptibility without other infectious or non-infectious manifestations, and the only PID that causes fungal disease in which CNS is a primary target tissue¹⁷. We previously demonstrated that *Candida* CNS disease in CARD9-deficiency is caused by a fungal- and brain-specific defect in neutrophil recruitment⁵. CNS neutropenia is now confirmed in several CARD9-deficient patients with CNS candidiasis^{7,37,38}. Nonetheless,

392 how CARD9 mediates protective neutrophil trafficking into the fungal-infected CNS remained
393 unclear.
394
395 Our analysis of mice deficient in several CLR, cytokine and chemokine circuits uncovered 1)
396 the functional redundancy among CLRs, which may suggest the presence of yet-undiscovered
397 CARD9-coupled receptors for driving tissue-specific antifungal defense; 2) the indispensable
398 role of the CARD9-partner MALT1 in controlling CNS fungal invasion independent of neutrophil
399 recruitment, which implies that *MALT1*^{-/-} patients may be at risk for CNS fungal disease; and 3)
400 the critical contribution of IL-1 β –CXCL1-mediated neutrophil recruitment for control of CNS
401 fungal invasion. CXCR2 was known to mediate neutrophil trafficking during viral infection,
402 parasitic meningitis³⁹ and fungal pneumonia⁴⁰, and herein we reveal its importance for
403 recruiting neutrophils during fungal CNS infection, principally through binding CXCL1. In
404 contrast, CCR1, CXCR1 and LTB4R1 are dispensable despite them regulating neutrophil
405 recruitment and function in other *C. albicans*-infected tissues¹³⁻¹⁵. These studies further
406 underscore the organ- and context-specific dependence on chemotactic molecules for
407 protective host immunity.

408
409 We showed that IL-1 β is required for CXCL1 induction, in line with earlier work which showed
410 IL-1 β –induced CXCL1 production controlling neutrophil accumulation during bacterial
411 peritonitis and autoimmune, traumatic or bacterial neuroinflammation^{10,41,42}. Importantly,
412 microglia are the primary myeloid cellular source of IL-1 β -dependent CXCL1 production *in*
413 *vivo*. During oral candidiasis, IL-1R is also required for neutrophil accumulation to the oral
414 mucosa⁸, as we showed for systemic infection in the brain. However, further attesting to the

415 presence of tissue-specific anti-*Candida* immune response cues, the IL-1R–dependent
416 response in the oral epithelium is largely controlled by IL-1 α released by damaged
417 keratinocytes⁸, whereas we found that IL-1 α plays a modest role in controlling brain fungal
418 invasion. In fact, IL-1 α release by both oral and vaginal epithelial cells is driven by exposure to
419 the fungal-secreted toxin Candidalysin¹⁹⁻²¹.

420

421 Candidalysin enables the establishment of *C. albicans* mucosal infections, since Candidalysin-
422 deficient strains are avirulent in these models^{19,21}. In contrast, we found that Candidalysin-
423 deficient strains are hyper-virulent for the brain, associated with decreased IL-1 β and CXCL1
424 production and impaired neutrophil recruitment. These results indicate that Candidalysin is not
425 only a classical virulence factor, but also an immune modulator, which exerts context-specific
426 effects on the immune system. We propose that this dual function of Candidalysin is the result
427 of a co-evolutionary event; the fungus developed an efficient toxin to damage host
428 membranes, and, in response, the host evolved a sensitive Candidalysin detection system to
429 defend against this common mucosal pathogen. Whether Candidalysin is recognized by a
430 specific microglial innate receptor to mediate the protective IL-1 β –CXCL1 axis is unclear, since
431 the toxin mediates cellular damage which could also activate glial cells. Therefore, identifying
432 how host epithelial and immune cells recognize Candidalysin merits investigation.

433

434 We found that Candidalysin selectively activates microglia for IL-1 β and CXCL1 production, a
435 self-renewing macrophage population that contributes towards neuroinflammation in
436 neurodegenerative disorders and promotes pathogen and dead cell clearance within the
437 CNS⁴³. Interestingly, downstream of Candidalysin-induced microglial IL-1 β secretion, which

occurs via c-Fos activation, we show that additional signals derived from astrocytes acting *in trans* are required for microglia to secrete CXCL1. Whether direct microglia-astrocyte contact is required or astrocyte-derived soluble factors acting on microglia are needed remains unknown. Indeed, microglia are known to interact with astrocytes to drive or suppress inflammation^{44,45}. Therefore, the molecular factors that drive microglia-astrocyte cross-talk within the fungal-infected brain warrant further investigation.

Lastly, we examined the dependence on CARD9 for the microglia-mediated, IL-1 β –CXCL1-dependent pathway that recruits protective neutrophils, using fully Card9-deficient and conditional microglia-specific *Card9*^{-/-} mice. We show that CARD9 is critical for c-Fos activation and for the production of both IL-1 β and CXCL1 by microglia in the infected CNS operating at the levels of both transcriptional pro-IL-1 β regulation and inflammasome activation for IL-1 β generation, with NLRP3 being at least partly involved, as shown with *Microsporium* infection⁴⁶. Together, these data shed light into the pathogenesis of inherited CARD9-deficiency by outlining a pathway of CARD9-dependent microglial production of sequential IL-1 β and CXCL1 that recruits protective neutrophils into the fungal-infected CNS.

Future studies should examine whether Card9 promotes microglial innate functions beyond orchestrating neutrophil recruitment such as fungal uptake and killing. Of note, the phenotype of microglia-specific conditional knockout mice is less severe than that of *Card9*^{-/-} mice, which may reflect the important role of astrocytes, which express Card9 post-infection⁵, in priming microglial CXCL1 production. Future work should examine whether non-CNS tissue-resident macrophages, such as Kupffer cells differentially depend on Card9 for IL-1 β –CXCL1-mediated

461 neutrophil recruitment, as previously shown for differential macrophage and dendritic cell-
462 induced Card9-dependent TNF- α ⁴⁷; this will help further understand the fungal infection CNS-
463 specificity in CARD9-deficiency. Beyond understanding the pathogenesis of inherited CARD9-
464 deficiency, our findings have important implications for recognizing the potential fungal
465 infection risk in patients who are increasingly receiving Syk inhibitors for autoimmune and
466 malignant diseases^{48,49}. Surveillance of Syk inhibitor-treated patients and research in
467 conditional Syk-deficient mice will help determine their CNS fungal disease risk.

468

469 In summary, we present evidence of an intricate host immune pathway that protects the CNS
470 from invading fungi. This work uncovers the complex interactions occurring between the host
471 and the most common human fungal pathogen within the CNS, and sheds novel mechanistic
472 light into the pathogenesis of inherited CARD9-deficiency.

473 **Acknowledgements**

474 This work was supported by the Intramural Research Program of the National Institute of
475 Allergy and Infectious Disease, National Institutes of Health, as well as NIH grants awarded to
476 T.M.H (R01 093808), S.G.F (R01AI124566) and S.R.L (R01CA161373). Additional funding
477 was provided by the Burroughs Wellcome Fund (awarded to T.M.H), the Wellcome Trust
478 (102705, 097377; awarded to G.D.B), the MRC Centre for Medical Mycology and the
479 University of Aberdeen (MR/N006364/1; awarded to G.D.B). The authors additionally thank C.
480 Huaman for care and screening of the *Malt1*^{-/-} mice, which were a kind gift to B.C.S. from T.
481 Mak and the University Health Network (Canada), and D. McGavern and F. Crews for
482 providing the murine glial cell lines.

483

484 **Author Contributions**

485 R.A.D. and M.S.L. designed the study. R.A.D., M.S., V.O., B.Z., and I.M.D. performed the
486 experiments. R.A.D., M.S., V.O., B.Z., I.M.D., T.M.H. and M.S.L. analyzed the data. B.C.S,
487 A.C.B, K.D.M-B, S.A.L, Y.I, S.G.F, G.D.B, B.H, J.R.N and T.M.H provided key reagents/mouse
488 lines and intellectual input into the experimental design regarding their use. R.A.D. and M.S.L
489 wrote the manuscript.

490

491 **Competing Interest Statement**

492 No competing interests exist.

493

494

495

References

1. Lionakis, M.S. & Levitz, S.M. Host control of fungal infections: lessons from basic studies and human cohorts. *Ann Rev Immunol* **36**, 157-191 (2018).
2. Drummond, R.A. & Lionakis, M.S. Mechanistic insights into the role of C-type lectin receptor/CARD9 signaling in human antifungal immunity. *Front Cell Infect Microbiol* **6**, <http://dx.doi.org/10.3389/fcimb.2016.00039> (2016).
3. Glocker, E.O., Hennigs, A., Nabavi, M., Schaffer, A.A., Woellner, C. *et al.* A homozygous CARD9 mutation in a family with susceptibility to fungal infections. *N Engl J Med* **361**, 1727-1735 (2009).
4. Lanternier, F., Pathan, S., Vincent, Q.B., Liu, L., Cypowyj, S. *et al.* Deep dermatophytosis and inherited CARD9 deficiency. *N Engl J Med* **369**, 1704-1714 (2013).
5. Drummond, R.A., Collar, A.L., Swamydas, M., Rodriguez, C.A., Lim, J.K. *et al.* CARD9-dependent neutrophil recruitment protects against fungal invasion of the central nervous system. *PLoS Pathog* **11**, e1005293 (2015).
6. Li, X., Utomo, A., Cullere, X., Choi, M.M., Milner, D.A., Jr. *et al.* The β -glucan receptor Dectin-1 activates the integrin Mac-1 in neutrophils via Vav protein signaling to promote *Candida albicans* clearance. *Cell Host Microbe* **10**, 603-615 (2011).
7. Drewniak, A., Gazendam, R.P., Tool, A.T.J., van Houdt, M., Jansen, M.H. *et al.* Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. *Blood* **121**, 2385-2392 (2013).
8. Altmeier, S., Toska, A., Sparber, F., Teijeira, A., Halin, C. *et al.* IL-1 coordinates the neutrophil response to *C. albicans* in the oral mucosa. *PLOS Pathog* **12**, e1005882 (2016).
9. Karki, R., Man, S.M., Malireddi, R.K.S., Gurung, P., Vogel, P. *et al.* Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against *Aspergillus* infection. *Cell Host Microbe* **17**, 357-368 (2015).
10. Biondo, C., Mancuso, G., Midiri, A., Signorino, G., Domina, M. *et al.* The interleukin-1 β /CXCL1/2/neutrophil axis mediates host protection against group B Streptococcal infection. *Infect Immun* **82**, 4508-4517 (2014).
11. Nemeth, T., Futosi, K., Sitaru, C., Ruland, J. & Mocsai, A. Neutrophil-specific deletion of the CARD9 gene expression regulator suppresses autoantibody-induced inflammation in vivo. *Nat Commun* **7**, 11004 (2016).

- 540
541 12. Wang, X., Zhang, R., Wu, W., Song, Y., Wan, Z. *et al.* Impaired specific antifungal
542 immunity in CARD9-deficient patients with phaeohyphomycosis. *J Invest Dermatol*
543 **138**, 607-617 (2018).
544
- 545 13. Lionakis, M.S., Fischer, B.G., Lim, J.K., Swamydas, M., Wan, W. *et al.* Chemokine
546 receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in
547 invasive candidiasis. *PLoS Pathog* **8**, e1002865 (2012).
548
- 549 14. Lee, E.K.S., Gillrie, M.R., Li, L., Arnason, J.W., Kim, J.H. *et al.* Leukotriene B4-mediated
550 neutrophil recruitment causes pulmonary capillaritis during lethal fungal sepsis. *Cell*
551 *Host Microbe* **23**, 121-133.e124 (2018).
552
- 553 15. Swamydas, M., Gao, J.-L., Break, T.J., Johnson, M.D., Jaeger, M. *et al.* CXCR1-
554 mediated neutrophil degranulation and fungal killing promote *Candida* clearance and
555 host survival. *Sci Trans Med* **8**, 322ra310-322ra310 (2016).
556
- 557 16. Ngo, L.Y., Kasahara, S., Kumasaka, D.K., Knoblaugh, S.E., Jhingran, A. *et al.*
558 Inflammatory monocytes mediate early and organ-specific innate defense during
559 systemic candidiasis. *J Infect Dis* **209**, 109-119 (2014).
560
- 561 17. Erwig, L.P. & Gow, N.A.R. Interactions of fungal pathogens with phagocytes. *Nat Rev*
562 *Microbiol* **14**, 163-176 (2016).
563
- 564 18. Zheng, X., Wang, Y. & Wang, Y. Hgc1, a novel hypha-specific G1 cyclin-related protein
565 regulates *Candida albicans* hyphal morphogenesis. *EMBO J* **23**, 1845-1856 (2004).
566
- 567 19. Moyes, D.L., Wilson, D., Richardson, J.P., Mogavero, S., Tang, S.X. *et al.* Candidalysin
568 is a fungal peptide toxin critical for mucosal infection. *Nature* **532**, 64-68 (2016).
569
- 570 20. Verma, A.H., Richardson, J.P., Zhou, C., Coleman, B.M., Moyes, D.L. *et al.* Oral
571 epithelial cells orchestrate innate type 17 responses to *Candida albicans* through the
572 virulence factor candidalysin. *Sci Immunol* **2** 10/1126/sciimmunol.aam8834 (2017).
573
- 574 21. Richardson, J.P., Willems, H.M.E., Moyes, D.L., Shoaie, S., Barker, K.S. *et al.*
575 Candidalysin drives epithelial signaling, neutrophil recruitment, and immunopathology at
576 the vaginal mucosa. *Infect Immun*, 10.1128/IAI.00645-00617 (2017).
577
- 578 22. Naglik, J.R., Challacombe, S.J. & Hube, B. *Candida albicans* secreted aspartyl
579 proteinases in virulence and pathogenesis. *Microbiol Mol Biol Rev* **67**, 400-428 (2003).
580
- 581 23. Gabrielli, E., Sabbatini, S., Roselletti, E., Kasper, L., Perito, S. *et al.* In vivo induction of
582 neutrophil chemotaxis by secretory aspartyl proteinases of *Candida albicans*. *Virulence*
583 **7**, 819-825 (2016).
584

- 585 24. Pericolini, E., Gabrielli, E., Amacker, M., Kasper, L., Roselletti, E. *et al.* Secretory
586 aspartyl proteinases cause vaginitis and can mediate vaginitis caused by *Candida*
587 *albicans* in mice. *mBio* **6**, e00724-00715 (2015).
588
- 589 25. Henn, A., Lund, S., Hedtjarn, M., Schrattenholz, A., Porzgen, P. *et al.* The suitability of
590 BV2 cells as alternative model system for primary microglia cultures or for animal
591 experiments examining brain inflammation. *Altex-Alternativen Zu Tierexperimenten* **26**,
592 83-94 (2009).
593
- 594 26. Hennessy, E., Griffin, É.W. & Cunningham, C. Astrocytes are primed by chronic
595 neurodegeneration to produce exaggerated chemokine and cell infiltration responses to
596 acute stimulation with the cytokines IL-1 β and TNF- α . *J Neurosci* **35**, 8411-8422 (2015).
597
- 598 27. Pineau, I., Sun, L., Bastien, D. & Lacroix, S. Astrocytes initiate inflammation in the
599 injured mouse spinal cord by promoting the entry of neutrophils and inflammatory
600 monocytes in an IL-1 receptor/MyD88-dependent fashion. *Brain Behav Immun* **24**, 540-
601 553 (2010).
602
- 603 28. Omari, K.M., John, G., Lango, R. & Raine, C.S. Role for CXCR2 and CXCL1 on glia in
604 multiple sclerosis. *Glia* **53**, 24-31 (2005).
605
- 606 29. Poeck, H., Bscheider, M., Gross, O., Finger, K., Roth, S. *et al.* Recognition of RNA virus
607 by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 β
608 production. *Nature Immunol* **11**, 63-69 (2009).
609
- 610 30. Pereira, M., Toulomousis, P., Wright, J., P Monie, T. & Bryant, C.E. CARD9 negatively
611 regulates NLRP3-induced IL-1 β production on *Salmonella* infection of macrophages.
612 *Nature Commun* **7**, 12874-12874 (2016).
613
- 614 31. Kasper, L., König, A., Koenig, P.-A., Gresnigt, M.S., Westman, J. *et al.* The fungal
615 peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in
616 mononuclear phagocytes. *Nature Commun* **9**, 4260 (2018).
617
- 618 32. Parkhurst, C.N., Yang, G., Ninan, I., Savas, J.N., Yates, J.R. *et al.* Microglia promote
619 learning-dependent synapse formation through BDNF. *Cell* **155**, 1596-1609 (2013).
620
- 621 33. Pappas, P.G., Lionakis, M.S., Arendrup, M.C., Ostrosky-Zeichner, L. & Kullberg, B.J.
622 Invasive candidiasis. *Nat Rev Dis Primers* **4**, 18026 (2018).
623
- 624 34. Lionakis, M.S., Netea, M.G. & Holland, S.M. Mendelian genetics of human susceptibility
625 to fungal infection. *Cold Spring Harbor Perspect Med* **4** 10.1101/cshperspect.a019638
626 (2014).
627
- 628 35. McCarthy, M.W., Kalasauskas, D., Petraitis, V., Petraitiene, R. & Walsh, T.J. Fungal
629 infections of the central nervous system in children. *J Pediatric Infect Dis Soc*,
630 <https://doi.org/10.1093/jpids/pix1059> (2017).

36. Drummond, R.A. & Lionakis, M.S. Candidiasis of the central nervous system in neonates and children with primary immunodeficiencies. *Curr Fungal Infect Rep* **12**, 92-97 (2018).
37. Cetinkaya, P.G., Ayvaz, D.C., Karaatmaca, B., Gocmen, R., Söylemezoğlu, F. *et al.* A young girl with severe cerebral fungal infection due to card 9 deficiency. *Clin. Immunol.* **191**, 21-26 (2018).
38. Lanternier, F., Mahdaviani, S.A., Barbati, E., Chaussade, H., Koumar, Y. *et al.* Inherited CARD9 deficiency in otherwise healthy children and adults with *Candida* species–induced meningoencephalitis, colitis, or both. *J Allergy Clin Immunol* **135**, 1558-1568 (2015).
39. Del Rio, L., Bennouna, S., Salinas, J. & Denkers, E.Y. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during *Toxoplasma gondii* infection. *J Immunol* **167**, 6503-6509 (2001).
40. Bonnett, C.R., Cornish, E.J., Harmsen, A.G. & Burritt, J.B. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of *Aspergillus fumigatus* conidia. *Infect Immun* **74**, 6528-6539 (2006).
41. Lévesque, S.A., Paré, A., Mailhot, B., Bellver-Landete, V., Kébir, H. *et al.* Myeloid cell transmigration across the CNS vasculature triggers IL-1 β -driven neuroinflammation during autoimmune encephalomyelitis in mice. *J Exp Med* **213**, 929-949 (2016).
42. Hanamsagar, R., Aldrich, A. & Kielian, T. Critical role for the AIM2 inflammasome during acute CNS bacterial infection. *J Neurochem* **129**, 704-711 (2014).
43. Prinz, M., Erny, D. & Hagemeyer, N. Ontogeny and homeostasis of CNS myeloid cells. *Nat Immunol* **18**, 385-392 (2017).
44. Shinozaki, Y., Shibata, K., Yoshida, K., Shigetomi, E., Gachet, C. *et al.* Transformation of astrocytes to a neuroprotective phenotype by microglia via P2Y1 receptor downregulation. *Cell Rep* **19**, 1151-1164 (2017).
45. Rothhammer, V., Borucki, D.M., Tjon, E.C., Takenaka, M.C., Chao, C.-C. *et al.* Microglial control of astrocytes in response to microbial metabolites. *Nature* **557**, 724-728 (2018).
46. Mao, L., Zhang, L., Li, H., Chen, W., Wang, H. *et al.* Pathogenic fungus *Microsporium canis* activates the NLRP3 inflammasome. *Infect Immun* **82**, 882-892 (2014).
47. Goodridge, H.S., Shimada, T., Wolf, A.J., Hsu, Y.-M.S., Becker, C.A. *et al.* Differential use of CARD9 by Dectin-1 in macrophages and dendritic cells. *J Immunol* **182**, 1146-1154 (2009).

677
678
679
680
681
682
683
684
685
686

48. Weinblatt, M.E., Kavanaugh, A., Genovese, M.C., Musser, T.K., Grossbard, E.B. *et al.* An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. *N Eng J Med* **363**, 1303-1312 (2010).
49. Flynn, R., Allen, J.L., Luznik, L., MacDonald, K.P., Paz, K. *et al.* Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. *Blood* **125**, 4085-4094 (2015).

687 Figure Legends

688

689 **Fig. 1: Functional redundance of CARD9-coupled C-type lectin receptors for protective**
690 **neutrophil recruitment to the fungal-infected brain. a**, *Card9*^{-/-} mice (n=4 animals) and their
691 wild-type controls (n=4 animals) were intravenously infected with *C. albicans* SC5314 and
692 analyzed for neutrophil counts by flow cytometry at 24 h post-infection (left; dose: 1.3×10^5
693 CFU) and fungal growth within the brain at 72 h post-infection (right; dose: 7×10^4 CFU). **b**,
694 Animals of the indicated genotype (WT n = 9 animals, *Clec7a*^{-/-} n = 6 animals; WT n = 12
695 animals, *Clec4n*^{-/-} n = 10 animals; WT n = 6 animals, *Clec4d*^{-/-} n = 6 animals; WT n = 6
696 animals, *Clec4e*^{-/-} n = 8 animals; WT n = 10 animals, *Clec7a*^{-/-}*Fcer1g*^{-/-} n = 9 animals) were
697 intravenously infected with *C. albicans* SC5314 (2×10^5 CFU for *Clec4d*^{-/-} and *Clec7a*^{-/-}*Fcer1g*^{-/-}
698 ^{-/-} and their controls; 1.3×10^5 all others) and analyzed for neutrophil counts by flow cytometry
699 at 24 h post-infection and **c**, fungal burdens in the brain at 24 and 72 h post-infection (WT n =
700 9 animals, *Clec7a*^{-/-} n = 6 animals; WT n = 10 animals, *Clec4n*^{-/-} n = 10 animals; WT n = 10
701 animals, *Clec4d*^{-/-} n = 10 animals; WT n = 6 animals, *Clec4e*^{-/-} n = 4 animals; WT n = 10
702 animals, *Clec7a*^{-/-}*Fcer1g*^{-/-} n = 9 animals). **d**, *Malt1*^{-/-} mice and their littermate controls were
703 infected as above and analyzed for fungal burdens in the brain (right; WT n = 7 animals, *Malt1*^{-/-}
704 ^{-/-} n = 5 animals) and neutrophil recruitment to the brain at 24 h post-infection (left; WT n = 5
705 animals, *Malt1*^{-/-} n = 5 animals). In all cases, 'wild type' refers to appropriate matched control
706 animals for each knock-out line for gender, age and genetic background. Individual points
707 represent different mice. Data is pooled from 2 independent experiments and is shown as
708 mean +/- SEM, and analyzed by unpaired two-tailed t-test (panel **a** [left], **b**) or two-tailed Mann
709 Whitney U-test (panel **a** [right], **c**, **d**). **P*<0.05, ***P*<0.01, ****P*<0.005, *****P*<0.001.

710

711 **Fig. 2: IL-1 β and CXCL1 mediate protective neutrophil recruitment to the fungal-infected**
712 **brain. a,b,** Animals deficient in elements of the IL-1R signaling pathway or **c,d,** chemokine
713 receptors and their ligands, were infected and analyzed for neutrophil recruitment at 24 h post-
714 infection (**a,c**) and control of fungal brain infection (**b,d**) as in Fig. 1. 'Wild type' refers to
715 appropriate matched control animals for each knock-out line for gender, age and genetic
716 background. Individual points represent different mice; (**a**) WT n = 8 animals, *Il1r*^{-/-} n = 8
717 animals; WT n = 7 animals, *Myd88*^{-/-} n = 6 animals; WT n = 12 animals, *Il1a*^{-/-} n = 12 animals;
718 WT n = 6 animals, *Il1b*^{-/-} n = 6 animals; WT n = 8 animals, *Il1a*^{-/-}*Il1b*^{-/-} n = 6 animals. (**b**) WT n
719 = 8 animals, *Il1r*^{-/-} n = 7 animals; WT n = 7 animals, *Myd88*^{-/-} n = 6 animals; WT n = 3-8
720 animals, *Il1a*^{-/-} n = 4-8 animals; WT n = 6 animals, *Il1b*^{-/-} n = 6 animals; WT n = 6 animals, *Il1a*^{-/-}
721 *Il1b*^{-/-} n = 6 animals. (**c**) WT n = 6 animals, *Ccr1*^{-/-} n = 6 animals; WT n = 11 animals, *Cxcr1*^{-/-}
722 n = 11 animals; WT n = 14 animals, *Cxcr2*^{-/-} n = 16 animals; WT n = 8 animals, *Cxcl1*^{-/-} n = 7
723 animals. (**d**) WT n = 6-7 animals, *Ccr1*^{-/-} n = 6-7 animals; WT n = 7-10 animals, *Cxcr1*^{-/-} n = 7-
724 10 animals; WT n = 8-10 animals, *Cxcr2*^{-/-} n = 7-10 animals; WT n = 6-8 animals, *Cxcl1*^{-/-} n =
725 5-7 animals. Data is pooled from 2-3 independent experiments and shown as mean \pm SEM,
726 analyzed by unpaired two-tailed t-test (panel **a, c**) or two-tailed Mann Whitney U-test (panel **b,**
727 **d**). **P*<0.05, ***P*<0.01, ****P*<0.005, *****P*<0.001.

728

729 **Fig. 3: Production of CXCL1 is dependent on IL-1 β in the fungal-infected brain. a,** Wild
730 type (n = 6/7 animals), *Cxcl1*^{-/-} (n = 5 animals) and *Il1b*^{-/-} (n = 6 animals) animals were infected
731 as in Fig. 1 and brains isolated at 24 h post-infection and analyzed for CXCL1 or IL-1 β
732 production by ELISA. Data is pooled from 2 independent experiments and analyzed by

733 unpaired two-tailed t-test. **b**, The relative proportions of myeloid cell populations (gated within
 734 live CD45⁺ singlets) in the uninfected (n = 6 animals) and 24 h infected WT (n = 6 animals)
 735 brain (left), and the relative proportion of myeloid cell populations producing CXCL1 (n = 3
 736 animals) or pro-IL-1 β (n = 9 animals) in the 24 h infected brain (right). For the latter, total
 737 CD45⁺CXCL1(or IL-1 β)⁺ cells were first gated and then cell types defined within this initial gate
 738 using lineage markers (see below), using samples from the unstimulated condition. Data is
 739 shown as the mean \pm SEM. **c**, Wild type (n = 3 animals) and *Il1b*^{-/-} mice (n = 4 animals) were
 740 infected with 2×10^5 *C. albicans* and brain cells analyzed for CXCL1 production by intracellular
 741 flow cytometry 24 h later. Brain cells were restimulated *ex vivo* with 62.5 μ g/mL depleted
 742 zymosan or 1 μ g/mL LPS for 4 h in the presence of 5 μ g/mL Brefeldin A. Representative plots
 743 from the LPS-stimulated condition are gated on microglia (top; CD45^{int} Ly6G⁻ CD11b⁺), Ly6C^{hi}
 744 monocytes (middle; CD45^{hi} Ly6C^{hi} Ly6G⁻ CD11b⁺) and neutrophils (bottom; CD45^{hi} Ly6C^{int}
 745 Ly6G^{hi} CD11b⁺), showing corresponding *Cxcl1*^{-/-} cells as gating controls. In all panels, 'wild
 746 type' refers to appropriate matched control animals for each knock-out line for gender, age and
 747 genetic background. Individual points represent different mice. Data shown as mean \pm SEM,
 748 and analyzed by unpaired two-tailed t-test. **P*<0.05, ***P*<0.01.

749

750 **Fig. 4: Fungal-derived Candidalysin promotes neutrophil recruitment and control of**
 751 **fungal growth in the brain. a,b,c,e**, Animals were infected with 2×10^5 CFU of the indicated
 752 *C. albicans* strains (parental strains, closed symbols; deficient mutants, open symbols) and
 753 analyzed as in Fig. 1 for fungal burdens (*hgc1* Δ/Δ n = 8 animals, *hgc1* Δ/Δ + *HGC1* n = 7
 754 animals; BWP17 n = 10 animals, *ece1* Δ/Δ n = 11 animals, *ece1* Δ/Δ + *ECE1* n = 10 animals,
 755 *ece1* Δ/Δ + *ECE1* _{Δ 184-279} n = 11 animals; CAI4 + Clp10 n = 6 animals, *sap4/5/6* Δ/Δ + Clp10 n =

6 animals) and neutrophil recruitment (*hgc1Δ/Δ* n = 10 animals, *hgc1Δ/Δ* + *HGC1* n = 10 animals; BWP17 n = 7 animals, *ece1Δ/Δ* n = 7 animals, *ece1Δ/Δ* + *ECE1* n = 7 animals, *ece1Δ/Δ* + *ECE1*_{Δ184-279} n = 11 animals; CAI4 + Clp10 n = 6 animals, *sap4/5/6Δ/Δ* + Clp10 n = 7 animals). Histology shown in (c) is from 24 h post-infection, stained with PAS. Scale bar is 50 μm. d, Whole brain homogenates from animals infected with indicated strains were isolated at 24 h post-infection and analyzed for IL-1β and CXCL1 using ELISA (BWP17 n = 8-10 animals, *ece1Δ/Δ* n = 8-10 animals, *ece1Δ/Δ* + *ECE1* n = 6-11 animals, *ece1Δ/Δ* + *ECE1*_{Δ184-279} n = 7-11 animals). Individual points represent different mice. Data is pooled from 2-4 independent experiments and shown as mean +/- SEM, analyzed by unpaired two-tailed t-test, or two-tailed Mann Whitney U-test (panel a, left). **P*<0.05, ***P*<0.01, ****P*<0.005; ns = not significant.

Fig. 5: Microglia produce IL-1β and CXCL1 in a Candidalysin-dependent manner.

Animals were infected with wild-type *C. albicans* (BWP17; closed bars) or a Candidalysin-null strain (*ece1Δ/Δ*; open bars), and brain cells isolated 24 h later. Brain leukocytes were restimulated as in Fig. 3, and intracellular staining for a, IL-1β (unstimulated, n = 8 animals; zymosan, n = 4 animals; LPS n = 6 animals) and b, CXCL1 (unstimulated, n = 12 animals; zymosan, n = 6 animals; LPS n = 9 animals) was analyzed by flow cytometry. Box-and-whisker plots show the minimum/maximum values (whiskers), the 25th/75th percentiles and the median. Data is pooled from 2-4 independent experiments and analyzed by unpaired two-tailed t-tests. **P*<0.05, ***P*<0.01. Representative staining is shown for LPS-stimulated microglia (gated as in Fig. 3) from wild-type mice infected with indicated strains, or BWP17-infected cytokine-deficient mutants as control.

779

780 **Fig. 6: Candidalysin activates microglial IL-1 β production via p38-cFos signaling and**
781 **promotes microglial CXCL1 production through astrocyte interactions.** BV-2 microglia
782 were seeded into 24-well plates at 5×10^5 per well and left to adhere for 2 h in the presence of
783 50 n g/mL LPS (for priming) before the addition of purified Candidalysin at the indicated
784 concentrations. Cell culture supernatants were analyzed for **a**, IL-1 β production or **b**, LDH
785 release after 24 h of stimulation. Data is shown with the mean \pm SEM, individual points
786 represent individual culture wells (n = 4). **c-d**, In some experiments, BV-2 cells were co-
787 cultured with 3×10^5 C8-D1A astrocytes, and CXCL1 production analyzed in the supernatant
788 by ELISA (n = 10 individual culture wells) or by intracellular flow cytometry (n = 3-5 individual
789 culture wells; data shown with the mean). In **d**, microglia and astrocytes were distinguished by
790 CD45 staining, and CXCL1 production assessed within CD45⁺ (microglia) and CD45⁻
791 (astrocyte) gates. Histogram is gated on CD45⁺ microglia. **e**, To measure cFos and pMKP1/2
792 activation, BV-2 cells were stimulated with the indicated Candidalysin concentrations for 30 or
793 120 min and BV-2 cells then lysed and analyzed for cFos and pMKP1/2 by immunoblot,
794 normalizing to β -actin. Immunoblots shown are representative of 2 independent experiments. **f**,
795 BV-2 cells were cultured in the presence of the indicated cFos and p38 inhibitors for 2 h prior
796 to stimulating with 20 μ M Candidalysin, and IL-1 β measured in the supernatant by ELISA after
797 24 h (data shown as mean \pm SEM; n = 6 individual culture wells). All data is pooled from 2
798 independent experiments and analyzed by one-way ANOVA. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$,
799 **** $P < 0.0001$.

800

Fig. 7: CARD9 is required for microglial pro-IL-1 β transcription, inflammasome activation, and CXCL1 production in the fungal-infected brain. **a,b**, *Card9*^{+/+} (n = 13 animals) and *Card9*^{-/-} (n = 13 animals) animals were infected with 2×10^5 CFU wild-type *C. albicans* (BWP17), and brain cells isolated 24 h later. Brain leukocytes were restimulated as in Fig. 4, and intracellular staining for pro-IL-1 β and CXCL1 analyzed by flow cytometry in total CD45⁺ cells (LPS-stimulated condition shown) (**a**) or microglia alone, normalized to *Card9*^{+/+} results (**b**). Panels **a,b** show pooled data from 4 independent experiments, analyzed with two-tailed unpaired t-test. Data shown as mean \pm SEM (**a**) or with minimum/maximum values (whiskers), the 25th/75th percentiles and the median (**b**). **c**, Microglia were FACS-sorted from pooled *Card9*^{+/+} (n = 4 animals) and *Card9*^{-/-} animals (n = 4 animals) at 24 h post-infection and analyzed by unpaired two-tailed t-test for *Il1b* expression by qRT-PCR, or **d,e**, the indicated proteins by immunoblot (Caspase and IL-1 β blots; WT n = 6 animals, *Card9*^{-/-} n = 7 animals; cFos blot; WT n = 10 animals, *Card9*^{-/-} n = 10 animals; NLRP3 blot; WT n = 8 animals, *Card9*^{-/-} n = 8 animals;). Graphs in (**d,e**) represent the band pixel density normalized to the wild type control, and are shown with mean \pm SEM and analyzed by unpaired two-tailed student t-tests. Example blots are representative of 3 independent FACS sorts/experiments; pooled data is shown in the graphs above. **f**, *Nlrp3*^{-/-} animals and their wild-type controls were infected with 1.3×10^5 CFU *C. albicans* and analyzed by unpaired two-tailed t-tests for neutrophil recruitment to the brain 24 h later (left; WT n = 9 animals, *Nlrp3*^{-/-} n = 8 animals) and by two-tailed Mann-Whitney U-test for fungal brain burdens at 72 h post-infection (right; WT n = 14 animals, *Nlrp3*^{-/-} n = 14 animals), as described in Fig. 1. **P* < 0.05, ***P* < 0.01, ****P* < 0.005.

Fig. 8: CARD9 is required specifically in microglia for neutrophil recruitment and control of fungal invasion in the CNS. **a**, *Card9^{fl/fl}Cx3cr1^{CreER-/-}* and *Card9^{fl/fl}Cx3cr1^{CreER+/-}* littermates (n=8-13) were tamoxifen-pulsed at 4-5 weeks of age, left to rest for 4-6 weeks and then infected with 1.3×10^5 CFU *C. albicans* (SC5314) intravenously and analyzed for brain and kidney fungal burdens (*Card9^{fl/fl}Cx3cr1^{CreER-/-}* n = 8-10 animals; *Card9^{fl/fl}Cx3cr1^{CreER+/-}* n = 8 animals), **b**, neutrophil recruitment to the brain at 24 h post-infection (*Card9^{fl/fl}Cx3cr1^{CreER-/-}* n = 13 animals; *Card9^{fl/fl}Cx3cr1^{CreER+/-}* n = 9 animals), and **c**, intracellular staining for pro-IL-1 β and CXCL1, as described in Fig. 3 (*Card9^{fl/fl}Cx3cr1^{CreER-/-}* n = 8 animals; *Card9^{fl/fl}Cx3cr1^{CreER+/-}* n = 8 animals). Data is pooled from 2-4 independent experiments and is shown as mean \pm SEM, analyzed by two-tailed Mann-Whitney U-tests (panel **a**) or two-tailed unpaired t-tests (panel **b**, **c**). **P*<0.05, ***P*<0.01.

Methods

Mice

Animals (males and females) were used at 8-12 weeks of age and were maintained in individually ventilated cages under specific pathogen-free conditions at the 14BS facility at the National Institutes of Health (Bethesda, MD, USA), the Memorial Sloan Kettering Cancer Center Comparative Medicine Shared Resources (New York, NY, USA), or the Medical Research Facility at the University of Aberdeen (UK). The following strains (and their respective WT controls/littermates) were obtained from the NIAID Taconic contract; *Cxcr2*^{-/-}, *Il1r*^{-/-}, *Ltb4r1*^{-/-}, *Fpr1*^{-/-}. All other strains and their respective controls/littermates were bred in-house at the NIH (*Clec7a*^{-/-}, *Clec4n*^{-/-}, *Clec4e*^{-/-}, *Myd88*^{-/-}, *Ccr1*^{-/-}, *Cxcr1*^{-/-}, *Cxcl1*^{-/-}, *Il1a*^{-/-}, *Il1b*^{-/-}, *Il1a*^{-/-}*Il1b*^{-/-}, *Nlrp3*^{-/-}, *Card9*^{fl/fl}*Cx3CR1*^{CreER+/-}), Memorial Sloan-Kettering Cancer Center (*Clec7a*^{-/-}*Fcer1g*^{-/-}), University of Aberdeen (*Clec4d*^{-/-}), or USUHS (*Malt1*^{-/-})⁵¹. Mice homozygous for the *Card9*^{tm1a} allele were purchased from the Wellcome Trust Sanger Institute (EUCOMM Project No. 44813), and these animals were bred with the FLPer deleter strain (Jackson Laboratories) to remove the FRT-flanked knock-out first cassette, generating *Card9*^{tm1c} homozygous mice (referred to as *Card9*^{fl/fl} in this manuscript)^{52,53}. Homozygous *Card9*^{fl/fl} animals were bred with heterozygous *Cx3cr1*^{CreER} transgenic animals (Jackson Laboratories) to generate *Card9*^{fl/fl}*Cx3cr1*^{CreER+/-} mice and littermate controls. Soon after weaning (~5-6 weeks old), *Card9*^{fl/fl}*Cx3cr1*^{CreER+/-} mice and their controls were treated with two 10mg doses of tamoxifen (Sigma) administered in corn oil by oral gavage, given 48 h apart. After 4-6 weeks, these animals were infected and analyzed as outlined in the Figure legends.

867 All experimentation conformed to conditions approved by the Animal Care and Use Committee
868 of the National Institute of Allergy and Infectious Diseases.

869

870 **Candidiasis Model and Fungal Burden Determination**

871 *Candida albicans* strains used in this study were SC5314, BWP17, *ece1* Δ/Δ , *ece1* Δ/Δ +*ECE1*,
872 *ece1* Δ/Δ +*ECE1* $_{\Delta 184-279}$ ¹⁹, CAI4+Clp10 and *sap4/5/6* Δ/Δ , and *hgc1* Δ/Δ and *hgc1* Δ/Δ + *HGC1*¹⁸.

873 Yeast was serially passaged three times in YPD broth, grown at 30°C with shaking for 18-24 h
874 at each passage. Yeast cells were washed in PBS, counted, and injected intravenously via the
875 lateral tail vein. Animals were infected with 1.3×10^5 colony forming units (CFU) for analysis at
876 24 h post-infection, or 7×10^4 CFU for analysis at 72 h post-infection, unless otherwise stated
877 in the corresponding Figure legends. For analysis of brain fungal burdens, animals were
878 euthanized and brains weighed, homogenized in PBS, and serially diluted before plating onto
879 YPD agar supplemented with Penicillin/Streptomycin (Invitrogen). Colonies were counted after
880 incubation at 37°C for 24-48 h.

881

882 **Analysis of Brain Neutrophil Recruitment by FACS**

883 Leukocytes were isolated from brains using previously described methods⁵⁴, resuspended in
884 PBS and stained with Live/Dead fluorescent dye (Invitrogen) for 10 min on ice. Cells were then
885 stained with fluorophore-conjugated antibodies in the presence of anti-CD16/32 and 0.5% BSA
886 for 30 min on ice. Samples were washed in PBS/0.5% BSA/0.01% sodium azide and acquired
887 using the BD Fortessa instrument equipped with BD FACS Diva software (BD Biosciences).
888 FlowJo (TreeStar) was used for the final analysis. Anti-mouse antibodies used in this study

889 were: CD45 (30-F11), CD11b (M1/70), both from eBiosciences, and Ly6G (1A8), Ly6C (AL-
890 21), both from BD Biosciences.

891

892 **Histology**

893 Brains were removed from infected mice at the indicated time points and fixed in 10% formalin
894 for 24 h before embedding in paraffin wax. Tissue sections were stained with periodic acid-
895 Schiff (PAS).

896

897 **Measurement of Cytokines and Chemokines in Brain Homogenates**

898 Infected brains were isolated at 24 h post-infection and homogenized in 1 mL PBS
899 supplemented with 0.05% Tween20 and protease inhibitor cocktail (Roche). Homogenized
900 brains were centrifuged twice to remove debris and resulting supernatants snap-frozen on dry
901 ice and stored at –80 °C prior to analysis. IL-1 β and CXCL1 concentrations in the
902 homogenates was determined by ELISA (R&D Systems), following the manufacturers'
903 instructions.

904

905 **Ex Vivo Restimulations and Intracellular FACS Analysis**

906 Animals were infected with 2×10^5 CFU of the indicated *C. albicans* strains intravenously, and
907 brain leukocytes isolated 24 h later. For these experiments, brains were first digested in RPMI
908 supplemented with 0.8 mg/mL Dispase (Gibco), 0.2mg/mL Collagenase Type 4 (Worthington),
909 and 0.1 mg/mL DNase (Roche) at 37 °C for 30 min, then pipetted vigorously to create a
910 homogenous suspension. These suspensions were centrifuged (1500 rpm, 5 min, 4 °C),
911 pellets resuspended in 5 mL 40% Percoll (GE Healthcare) and centrifuged again at 1700 rpm

for 20 min at 4 °C to remove myelin. Cell pellets were washed in RPMI supplemented with 10% heat-inactivated fetal bovine serum and Penicillin/Streptomycin (Invitrogen), and added to FACS tubes for stimulations. Cells were incubated for 4 h at 37 °C in the presence of 5 µg/mL Brefeldin A (Sigma) and, where indicated, 1 µg/mL LPS (Sigma) or 62.5 µg/mL depleted zymosan (Sigma). After stimulation, cells were washed in PBS and stained for surface markers as above. Fixation/permeabilization was performed with the eBioscience Foxp3 staining kit, and staining for CXCL1 (IC4532R, from R&D Systems) or pro-IL-1β (NJTEN3; from eBioscience) performed overnight at 4 °C. Samples were washed once in PBS/0.5% BSA/0.01% sodium azide prior to acquisition using the BD Fortessa instrument equipped with BD FACS Diva software (BD Biosciences). FlowJo (TreeStar) was used for the final analysis. CXCL1⁺ and pro-IL-1β⁺ cells were determined by employing similar staining and gating in animals deficient in these mediators (*Cxcl1*^{-/-}, *Il1b*^{-/-}) as negative controls.

Cell Culture and Candidalysin Stimulations

BV-2 cells were kindly provided by F. Crews (University of North Carolina School of Medicine). C8-D1A astrocytes were kindly provided by D. McGavern (NINDS, NIH). Details regarding the validation and use of these cell lines are provided in the Life Sciences Reporting Summary. BV-2 were maintained at 37 °C, 5% CO₂ in RPMI supplemented with L-glutamine and HEPES (pH 7.0 – 7.4; Corning), 10% heat-inactivated fetal bovine serum and Penicillin/Streptomycin (Invitrogen). DMEM media was used as the base media for C8-D1A culture, with the same supplements as listed above and cultured as for BV-2. For BV-2 single culture experiments, cells were lifted using cell scrapers and seeded into 24 well-plates at 5 × 10⁵ cells/well (BV-2) and left to adhere for 2 h at 37°C with either: 50 ng/mL LPS (Sigma), T-5224 (APExBIO)

935 and/or SB203580 (Adipogen); see Figure legends for details of each experiment. After 2 h,
936 recombinant Candidalysin peptide (Peptide Protein Research) was added to the cells at the
937 indicated concentrations and incubation at 37 °C continued. For co-culture experiments, $3 \times$
938 10^5 C8-D1A were added to each well of a 24 well-plate and incubated overnight at 37 °C. BV-2
939 cells and Candidalysin were added as described above. In both types of experiments,
940 supernatants or cells were collected at the indicated time points after Candidalysin addition
941 and analyzed for IL-1 β and CXCL1 by ELISA (R&D Systems), CXCL1 staining by intracellular
942 flow cytometry, or by immunoblot.

943

944 **Immunoblot Analysis**

945 Whole cell lysates were suspended in RIPA buffer containing protease and phosphatase
946 inhibitors (Thermo Scientific). Lysates were separated in SDS-PAGE and transferred to a
947 nitrocellulose membrane, 0.2 μ m (Bio-Rad Laboratories). The membrane was incubated with
948 the following primary antibodies: phospho-MPK1/MPK2 polyclonal [Ser296, Ser318] (Thermo
949 Scientific) and c-Fos (Cell Signaling), IL-1 β [3A6] (Cell Signaling), Caspase-1 p20 [Casper-1]
950 (Adipogen Life Sciences) (Thermo Scientific), NLRP3 [D4D8T] (Cell Signaling). Normalization
951 was performed by probing the membrane with β -Actin antibody (Cell Signaling).

952 Chemiluminescence detection was performed with ClarityTM Western ECL Substrate (Bio-Rad
953 Laboratories), using the ChemiDocTM MP Imaging System (Bio-Rad).

954

955 **FACS/MACS Sorting of Microglia**

956 Wild-type animals were infected with 1.3×10^5 CFU SC5314 and euthanized at 24 h post-
957 infection. Brains were digested as above and leukocytes stained with sterile antibodies⁵⁵.

958 Ly6C^{hi} monocytes (CD45^{hi} CD11b⁺ Ly6C^{hi} Ly6G⁻) and microglia (CD45^{lo} CD11b⁺ Ly6G⁻ Ly6C⁻)
959 were FACS-sorted into sterile sorting buffer (HBSS supplemented with 2 mM EDTA, 10 %
960 FCS, 100 U/mL penicillin, 100 µg/mL streptomycin) using a FACS Aria instrument for
961 downstream qRT-PCR and immunoblot analyses. Purity of cells were greater than >95%, on
962 average. In some experiments (qRT-PCR of CLRs in brain-resident microglia; **Supplementary**
963 **Fig. 1**), microglia were instead sorted by magnetic separation using anti-CD11b microbeads
964 (Miltenyi). Cells were then centrifuged (1500 rpm 5 min, 4 °C) and resuspended in Trizol for
965 RNA purification or RIPA buffer for downstream immunoblot analysis. Depending on the
966 experiment, up to 5 animals were pooled for individual sorts, or individual mice were analyzed
967 separately (see Figure legends for details).

968

969 **Generation of cDNA and qRT-PCR**

970 RNA was extracted from sorted brain myeloid cells (defined using the gating strategy shown in
971 **Supplementary Fig. 2**) using Trizol (Invitrogen) and the RNeasy kit (Qiagen) per the
972 manufacturer's protocol. Purified RNA was used as a template for cDNA generation using the
973 qScript cDNA SuperMix kit (Quanta Biosciences) with oligodT and random primers.
974 Quantitative PCR was performed by TaqMan detection (PerfeCTa qPCR FastMix ROX;
975 Quanta BioSciences) with the 7900HT Fast Real-Time PCR System (Applied Biosystems). All
976 qPCR assays were performed in duplicate and the relative gene expression of each gene was
977 determined after normalization with GAPDH transcript levels using the $\Delta\Delta CT$ method. TaqMan
978 primers/probes (*Clec7a*, *Clec4n*, *Clec4d*, *Clec4e*, *Il1b*, *Card9*, *Gapdh*) were predesigned by
979 Applied Biosystems.

980

981 **Statistics**

982 Statistical analyses were performed using GraphPad Prism 7.0 software. Details of individual
983 tests are included in the figure legends. In general, data was tested for normal distribution by
984 Kolmogorov-Smirnov normality test and analyzed accordingly by two-tailed unpaired t-tests or
985 two-tailed Mann Whitney U-test. In cases where multiple data sets were analyzed, two-way
986 ANOVA was used with Bonferroni correction. In all cases, *P* values <0.05 were considered
987 significant. Further details relating to power calculations, randomization and blinding are
988 described in the Life Sciences Reporting Summary.

989

990 **Data Availability**

991 The data that support the findings of this study are available from the corresponding authors
992 upon request.

993 **Methods-only References**

994

995 51. Ruland, J., Duncan, G.S., Wakeham, A., Mak, T.W. Differential requirement for Malt1 in T
996 and B cell antigen receptor signaling. *Immunity* **19**(5), 749-58 (2003)

997

998 52. Tay, T.L., Mai, D., Dautzenberg, J., Fernandez-Klett, F., Lin, G. *et al.* A new fate mapping
999 system reveals context-dependent random or clonal expansion of microglia. *Nat Neurosci* **20**,
1000 793-803 (2017)

1001

1002 53. Goldmann, T., Wieghofer, P., Muller, P.F., Wolf, Y., Varol, D. *et al.* A new type of microglia
1003 gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. *Nat Neurosci* **16**,
1004 1618-1626 (2013)





1005


1006 54. Lionakis, M.S., Lim, J.K., Lee, C.C.R. & Murphy, P.M. Organ-specific innate immune
1007 responses in a mouse model of invasive candidiasis. *J Innate Immun* **3**, 180-199 (2011)




1008


1009 55. Cougnoux, A., Drummond, R.A., Collar, A.L., Iben, J.R., Salman, A. *et al.* Microglia
1010 activation in Niemann-Pick disease, type C1 is amenable to therapeutic intervention. *Hum Mol*
1011 *Genet* **27**, 2076-2089 (2018)

1012


a**b****c****d**




a**b****c**








BWP17



ece1 $\Delta\Delta$



a**b****c****d****e****f**